Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database. (Q51248618)

2 April 2018

title

Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database. (English)

1 reference

2 April 2018

0 references

Surakit Nathisuwan

2

1 reference

ORCID Public Data File 2021

author name string

Pornwalai Boonmuang

1

1 reference

2 April 2018

Nathorn Chaiyakunapruk

3

1 reference

2 April 2018

Wimon Suwankesawong

4

1 reference

2 April 2018

Pattreya Pokhagul

5

1 reference

2 April 2018

Nattawat Teerawattanapong

6

1 reference

2 April 2018

Pairin Supsongserm

7

1 reference

2 April 2018

publication date

25 April 2013

1 reference

2 April 2018

published in

Drug Safety

1 reference

2 April 2018

volume

36

1 reference

2 April 2018

issue

9

1 reference

2 April 2018

page(s)

779-787

1 reference

2 April 2018

https://scigraph.springernature.com/pub.10.1007/s40264-013-0055-5

exact match

0 references

cites work

International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Safety and statin therapy: reconsidering the risks and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Prevalence of musculoskeletal pain and statin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Withdrawal of cerivastatin from the world market

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Risk factors for statin-associated rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Statin safety: an assessment using an administrative claims database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

HMG-CoA reductase inhibitors and myotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

FDA adverse event reports on statin-associated rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Safety and efficacy of statins in Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Safety of herbal products in Thailand: an analysis of reports in the thai health product vigilance center database from 2000 to 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Relationship between coronary events and serum cholesterol during 10 years of low-dose simvastatin therapy: long-term efficacy and safety in Japanese patients with hypercholesterolemia in the Japan Lipid Intervention Trial (J-LIT) Extension 10 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Statin-associated rhabdomyolysis: is there a dose-response relationship?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Possible colchicine rhabdomyolysis in a fluvastatin-treated patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Cytoskeletal myotoxicity from simvastatin and colchicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Acute myopathy in a patient with concomitant use of pravastatin and colchicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Role of P-glycoprotein in statin drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Colchicine in clinical medicine. A guide for internists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-013-0055-5

Rhabdomyolysis induced by co-administration of fluvastatin and colchicine

21 January 2018

1 reference

12 December 2020

Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use.

1 reference

12 December 2020

British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout

1 reference

12 December 2020

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial

1 reference

12 December 2020

Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid

1 reference

12 December 2020

Colchicine-induced rhabdomyolysis in a heart/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin

1 reference

12 December 2020

Clinical practice. Gout

1 reference

12 December 2020

Rhabdomyolysis in a patient treated with colchicine and atorvastatin

1 reference

12 December 2020

HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre

1 reference

12 December 2020

Pattern of statins' utilization at Ramathobodi Hospital, 2005 to 2007.

1 reference

12 December 2020

Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout

1 reference

12 December 2020

Risk factors for rhabdomyolysis with simvastatin and atorvastatin

1 reference

12 December 2020

New approaches to drug safety: a pharmacovigilance tool kit.

1 reference

12 December 2020

Lipid-lowering treatment in hypercholesterolemic patients: the CEPHEUS Thailand survey

1 reference

12 December 2020

10.1007/S40264-013-0055-5

Identifiers

DOI

1 reference

2 April 2018

PubMed ID

23615756

1 reference

2 April 2018